Disclosures for "Design and Rationale of TRITON-PN, a Phase Three Study to Evaluate the Efficacy of Nucresiran in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy"
-
Laura Piera Obici has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alnylam. Laura Piera Obici has received personal compensation in the range of $500-$4,999 for serving as a Consultant for AstraZeneca. Laura Piera Obici has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novo Nordisk. Laura Piera Obici has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for BridgeBio. Laura Piera Obici has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for AstraZeneca. Laura Piera Obici has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Alnylam.
-
Dr. Cardenas-Soto has nothing to disclose.
-
Dr. Waddington Cruz has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Pfizer. Dr. Waddington Cruz has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Ionis. Dr. Waddington Cruz has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Astra Zeneca. Dr. Waddington Cruz has received personal compensation in the range of $500-$4,999 for serving as a Consultant for PTC. Dr. Waddington Cruz has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alnylam. Dr. Waddington Cruz has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sobi. Dr. Waddington Cruz has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Pfizer. Dr. Waddington Cruz has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Ionis. Dr. Waddington Cruz has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for PTC. Dr. Waddington Cruz has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for NovoNordisk.
-
Dr. Plante-Bordeneuve has nothing to disclose.
-
Prof. Losada has nothing to disclose.
-
Dr. Brannagan has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi. Dr. Brannagan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Intellia. Dr. Brannagan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Astra Zenica. Dr. Brannagan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Annexon. The institution of Dr. Brannagan has received research support from Alnylam. The institution of Dr. Brannagan has received research support from Abcuro. The institution of Dr. Brannagan has received research support from Ionis. The institution of Dr. Brannagan has received research support from Vertex. The institution of Dr. Brannagan has received research support from NMD Pharma.
-
Prof. Gillmore has received personal compensation in the range of $0-$499 for serving as a Consultant for Alnylam, ATTRalus, Astrazeneca, Bayer, Bridgebio, Intellia, Lycia, Pfizer. Prof. Gillmore has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Alnylam, Bayer, Intellia, Astrazeneca. Prof. Gillmore has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for Alnylam, Bayer, AstraZeneca, Pfizer, Alexion.
-
John L. Berk has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alnylam Pharmaceuticals. John L. Berk has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Ionis Pharmaceuticals. John L. Berk has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Astra Zeneca/IONIS. John L. Berk has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eidos/BridgBio. John L. Berk has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Intellia Therapeutics. John L. Berk has received research support from Alnylam . John L. Berk has received research support from Ionis. John L. Berk has received research support from Eidos/Bridgbio.
-
Ms. Li has stock in Alnylam Pharmaceuticals. Ms. Li has stock in Pfizer. Ms. Li has stock in Moderna.
-
Dr. Lau has received personal compensation for serving as an employee of Alnylam Pharmaceuticals. Dr. Lau has received personal compensation in the range of $10,000-$49,999 for serving as an Expert Witness for mctlaw. Dr. Lau has stock in Alnylam Pharmaceuticals.
-
Dr. Gonzalez Duarte has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Alnylam. Dr. Gonzalez Duarte has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Astra Zeneca. Dr. Gonzalez Duarte has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Alnylam . The institution of Dr. Gonzalez Duarte has received research support from Pfizer.